Om

Shaanxi Micot Pharmaceutical Technology Co., Ltd. is a biotechnology company based in Xi’an, China, founded in 2007. The company focuses on the discovery, development, and commercialization of dual- and multi-specific peptide drugs. Its research is concentrated on metabolic diseases, as well as cardiovascular and cerebrovascular conditions, addressing areas of significant unmet clinical need. Shaanxi Micot Pharmaceutical Technology Co., Ltd. operates R&D and related activities across multiple locations in China and the United States, leveraging a proprietary platform for screening and optimizing multi-target peptide therapeutics. The company’s pipeline includes several innovative clinical-stage candidates, notably MT1013, a dual-target receptor agonist peptide in advanced clinical development for secondary hyperparathyroidism associated with chronic kidney disease. Through its focus on first-in-class and best-in-class peptide therapies, Shaanxi Micot Pharmaceutical Technology Co., Ltd. plays a specialized role in the pharmaceutical market, supplying innovation-driven drug candidates and partnering with other biopharmaceutical companies for regional commercialization and late-stage development.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SHAANXI MICOT PHARMACEUTICAL TECHNOLOGY CO MED ENDAVU: Køb Shaanxi Micot Pharmaceutical Technology Co ($2335) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Shaanxi Micot Pharmaceutical Technology Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.